Enanta's NASH drug barely meets main goal in mid-stage study

A platoon of drug developers big and small has long been working on combating NASH, a fatty liver disease that has ravaged the developed world. On Wednesday, Enanta Pharmaceuticals unveiled data from a short mid-stage study which suggested its liver drug had — by a minuscule margin — met the main goal in NASH patients.